Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: One of the biggest breakthroughs that we've had for multiple myeloma is the first FDA-approved engineered T-cell therapy. It happened midway through the year in the spring, giving us the approval for the bb2121 product, also known as ide-cel [idecabtagene vicleucel; Abecma], for patients with relapsed or refractory multiple myeloma [after 4 or more prior lines of therapy]. That's probably the biggest breakthrough but we've also had some interesting other breakthroughs, which include approvals of certain forms of daratumumab (Darzalex), for example, the subcutaneous form, in conjunction with carfilzomib (Kyprolis) and dexamethasone for relapsed or refractory disease in [patients who received] 1 to 3 prior lines [of therapy]. Similarly, isatuximab (Sarclisa), carfilzomib, and dexamethasone has also been approved. We have a lot more options for our patients in the relapsed or refractory setting.
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
